Stock Price
7.55
Daily Change
-4.55%
Yearly
-84.23%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agios Pharmaceuticals 31.03 -0.11 -0.35% -32.48%
Applied Genetic Technologies 1.67 -0.07 -4.02% -64.16%
Alnylam Pharmaceuticals 138.62 -0.57 -0.41% -18.92%
Alexion Pharmaceuticals 182.50 0 0% 70.54%
Amgen 231.30 -2.53 -1.08% -8.35%
Arrowhead Research 53.79 -0.34 -0.63% -35.53%
Avrobio Inc 1.89 0 0% -87.34%
Biogen 230.81 -3.00 -1.28% -14.60%
Bluebird Bio 7.55 -0.36 -4.55% -84.23%
BioMarin Pharmaceutical 86.00 -0.71 -0.82% -2.26%
Dicerna Pharmaceuticals 38.22 0.22 0.58% 71.54%
Gilead Sciences 69.07 -1.36 -1.93% 1.59%
Intercept Pharmaceuticals 17.45 0.89 5.37% -38.66%
Immunogen 5.84 -0.08 -1.35% -25.89%
Incyte Corp 74.78 -0.23 -0.31% -22.40%
Ionis Pharmaceuticals 30.32 0.20 0.66% -51.52%
Moderna Inc 174.07 -12.54 -6.72% 39.10%
Mirati Therapeutics 120.81 4.83 4.16% -43.23%
Nektar Therapeutics 12.14 0.42 3.58% -28.21%
Novartis 81.46 -0.64 -0.78% -5.29%
Pfizer 53.54 -0.57 -1.05% 46.68%
PTC Therapeutics 41.14 -0.30 -0.72% -35.51%
Ultragenyx Pharmaceutical 66.75 -0.92 -1.36% -50.61%
Regeneron Pharmaceuticals 618.11 6.89 1.13% 13.99%
Seattle Genetics 132.55 2.26 1.73% -30.53%
Sangamo BioSciences 6.02 0.09 1.52% -60.96%
Sarepta Therapeutics 63.15 -2.97 -4.49% -34.74%
Vertex Pharmaceuticals 230.84 -0.23 -0.10% -2.48%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%

Indexes Price Day Year
NASDAQ 14340 -166.64 -1.15% 6.56%
US2000 2063 -33.44 -1.60% -4.53%

Bluebird Bio
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.